综合性脑奥米克方法突出显示了阿尔茨海默氏症痴呆症中的sn-1 lysophosphatidylethanolamine
Chih-Yu Chen1, Kristal Maner-Smith1, Manoj Khadka2
1Emory Integrated Metabolomics and Lipidomics Core, Emory University School of Medicine, Atlanta, GA, USA.
Nature communications
|November 1, 2025
概括
lysophosphatidylethanolamine (LPE) 和 lysophosphatidylcholine (LPC) 脂质在症状性阿尔茨海默氏症 (AD) 中较低. 较低的LPE/LPC水平与认知衰退和AD病理相关,这表明LPE 22:6是潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 老年学是一门学科.
背景情况:
- 特定脂类物种在阿尔茨海默病 (AD) 病原发生中的作用尚未完全理解.
- 识别脂质生物标志物对于理解AD的认知功能和神经病理变化至关重要.
研究的目的:
- 研究与阿尔茨海默病 (AD) 认知功能和神经病理学相关的脂质组生物标志物.
- 将脂质组学与蛋白质组学数据整合起来,以便对AD进行全面的分子分析.
主要方法:
- 在ROS和MAP队列中的316个死后大脑上使用非向质谱法.
- 将参与者分为对照组,无症状AD (AAD) 和症状AD (SAD) 组.
- 集成的脂组学数据与来自同一个人的非向蛋白质组学.
主要成果:
- 与对照组或AAD相比,LPE和LPC物种在SAD中明显较低.
- 脂质蛋白网络分析显示,LPE/LPC模块与MAPK/代谢,后突触密度和细胞-ECM相互作用通路相关.
- LPE 22:6显著降低了SAD,并影响了与突触可塑性和神经传递相关的蛋白质变化,与更好的认知和减少的神经病理相关.
结论:
- 较低水平的LPE和LPC脂质与症状性阿尔茨海默病有关.
- LPE 22:6 可能作为潜在的脂质特征和阿尔茨海默病的治疗点,影响突触可塑性和认知功能.
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801